Quantum-Si Incorporated - Ordinary Shares - Class A Aktie News

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Highlights Significant Development Advancements for ProteusTM and Industry Leading Technology Pipeline at Investor & Analyst Day.

Quantum-Si incorporated ( QSI ) Analyst/Investor Day November 19, 2025 10:00 AM EST Company Participants Jeffrey Hawkins - President, CEO & Director Todd Rearick - Chief Technology Officer John Vieceli - Chief Product Officer Brian Reed Conference Call Participants Kyle Mikson - Canaccord Genuity Corp., Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Scot...

BRANFORD, Conn.--(BUSINESS WIRE)--QSI to Highlight Significant Proteus™ Platform Dev Progress & Provide Insights into Company's Industry Leading Tech Pipeline at Investor & Analyst Day.

Quantum-Si incorporated ( QSI ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Risa Lindsay Jeffrey Hawkins - President, CEO & Director Jeffry Keyes - CFO & Treasurer Conference Call Participants Alexander Vukasin - Canaccord Genuity Corp., Research Division Scott Henry - Alliance Global Partners, Research Division Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Res...

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si Reports Third Quarter 2025 Financial Results. Announces Successful Sequencing on Prototype Proteus Unit, Development Program is On-Track.

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum.

BRANFORD, Conn.--(BUSINESS WIRE)--Quantum-Si to Report Third Quarter 2025 Financial Results on November 5, 2025.

Quantum-Si's (QSI -4.02%) shares weren't quite the picture of health as the trading week came to an end. Investors, concerned about the healthcare technology company potentially making dilutive secondary share issues, traded out of the stock to leave it with a nearly 5% loss on the day.